Abstracts tagged "Psoriatic arthritis"

Abstract Number: 0362 • ACR Convergence 2020
Patients with Psoriatic Arthritis Treated with Guselkumab Achieved Psoriasis-Related Symptom-Free State and Had No Skin Condition Impact on Their Health Related Quality of Life
Jan Dutz¹, Joseph Merola², Chenglong Han³, Alexa Kollmeier⁴, Bei Zhou³, Prasheen Agarwal³, Ya-Wen Yang⁵, May Shawi⁶ and Atul Deodhar⁷, ¹Vancouver General Hospital, Vancouver, Canada, ²Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Global Services, LLC, Malvern/Horsham, PA, ⁶Janssen Global Services, LLC, Toronto, ON, Canada, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Guselkumab (GUS), a monoclonal antibody that specifically binds to the p19 subunit of IL-23, is approved for psoriasis. In the DISCOVER-2 Phase 3 trial…
Abstract Number: 0502 • ACR Convergence 2020
Integration of Clinical and Protein Markers Through Machine Learning to Distinguish Patients with Psoriasis Arthritis from Those with Psoriasis Without Psoriatic Arthritis
Sara Rahmati¹, Fatima Abji¹, Proton Rahman² and Vinod Chandran³, ¹University Health Network, Toronto, ON, Canada, ²Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive inflammatory arthritis that occurs in about 24% of psoriasis patients. Early diagnosis of PsA is associated with better…
Abstract Number: 0884 • ACR Convergence 2020
Comparison of Disease Control Thresholds in Psoriatic Arthritis: Results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Philip Mease¹, Robert McLean², Taylor Blachley², Laura Anatale-Tardiff³, Christopher Saffore⁴, Patrick Zueger⁴ and Alexis Ogdie⁵, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Waltham, ⁴AbbVie Inc., North Chicago, IL, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: There is no single accepted measure of low/minimal disease activity (LDA/MDA) for patients with PsA; thus, describing the characteristics of real-world patients meeting different…
Abstract Number: 0940 • ACR Convergence 2020
In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
Giovanni Adami¹, Angelo Fassio¹, Elisabetta Gerratana², Alessandro Giollo¹, Camilla Benini¹, Luca Idolazzi¹, Elisabetta Vantaggiato¹, Davide Gatti¹ and Maurizio Rossini¹, ¹Rheumatology Unit, University of Verona, Verona, Italy, ²Rheumatology Unit, University of Messina, Messina, Italy
Background/Purpose: Long-term nociceptive pain, as in inflammatory arthritides, can cause Central Sensitization (CS) to pain. CS Inventory (CSI) is a validated screening instrument for clinicians to…
Abstract Number: 1339 • ACR Convergence 2020
COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Rebecca Haberman¹, Rochelle Castillo¹, Alan Chen², Di Yan¹, Deborah Ramirez², Vaish Sekar², Robert Lesser², Gary Solomon², Andrea Neimann², Rebecca Blank¹, Peter Izmirly³, Dan Webster⁴, Alexis Ogdie⁵, Andrea Troxel², Samrachana Adhikari² and Jose Scher¹, ¹NYU School of Medicine, New York City, ²NYU Langone Health, New York City, ³New York University, New York, NY, ⁴Sage Bionetworks, Seattle, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: The COVID-19 pandemic has quickly emerged as the most challenging global health crisis in a generation. Affecting initially China, New York City (NYC) quickly…
Abstract Number: 1372 • ACR Convergence 2020
Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis and Axial Involvement
Atul Deodhar¹, Roberto Ranza², Fabiana Ganz³, Tianming Gao⁴, Jaclyn K Anderson⁴ and Andrew Östör⁵, ¹Oregon Health & Science University, Portland, OR, ²Hospital de Clinicas, Universidade Federal de Uberlândia, Uberlândia, Brazil, ³AbbVie Inc., Baar, Switzerland, ⁴AbbVie Inc., North Chicago, IL, ⁵Cabrini Medical Center, Monash University, Malvern, Victoria, Australia
Background/Purpose: Upadacitinib (UPA) has demonstrated efficacy for the treatment of AS in patients (pts) who were NSAID inadequate responders (IR).1 Pts with psoriatic arthritis (PsA)…
Abstract Number: 1848 • ACR Convergence 2020
Identification of Native and Citrullinated Autoantibodies to Psoriasis Related-antigen PsoP27 in Synovial Fluids of Patients with Psoriatic Arthritis
Marina Slobodkin¹, Smadar Gertel¹, Ari Polachek², Victoria Furer³ and Ori Elkayam⁴, ¹Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ³Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁴Tel Aviv Sourasky Medical Center,, Tel aviv, Israel
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease with no serological biomarkers, hence diagnosis is based on clinical evaluation alone. PsA is closely associated…
Abstract Number: 0307 • ACR Convergence 2020
Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Alexis Ogdie¹, Martin Rozycki², Theresa Arndt², Cheng Shi³, Nina Kim⁴ and Peter Hur³, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²HVH Precision Analytics, LLC, Wayne, PA, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴The University of Texas at Austin; Baylor Scott and White Health, Austin, TX
Background/Purpose: In developing algorithms within claims databases that may inform how to find patients with psoriatic arthritis (PsA) prior to diagnosis, it is important to…
Abstract Number: 0323 • ACR Convergence 2020
Residual Symptoms in Patients with PsA Who Are in Very Low Disease Activity According to Physician Assessments
Alexis Ogdie¹, Soumya Reddy², Ethan Craig¹, Jose Scher³, Yvonne Lee⁴, Jessica Walsh⁵ and M. Elaine Husni⁶, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³NYU School of Medicine, New York City, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ⁶Cleveland Clinic, Cleveland, OH
Background/Purpose: Discrepancy between patient and provider assessments of disease activity is well described in psoriatic arthritis (PsA) and other inflammatory arthritides. Patients often have low…
Abstract Number: 0340 • ACR Convergence 2020
Neuropathic Pain Relationship with Comorbidity in Psoriatic Arthritis Patients and Its Influence on Disease Activity
Maria Elisa Acosta¹, Olga Compán², Sonia Pastor¹, Guadalupe Manzano Canabal¹, Luis Gomez-Lechon Quiros³, Cristina Hidalgo Calleja⁴, Olga Martinez Gonzalez⁵, Ana Isabel Turrión¹, Javier Del Pino-Montes¹ and Carlos Montilla Morales¹, ¹Hospital Universitario de Salamanca, Salamanca, Spain, ²Hospital Universitario de Salamanca, ´Salamanca, Spain, ³Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ⁴Hospital Universitario Salamanca, Salamanca, Spain, ⁵Hospital Universitario de Salamanca, Zamora, Spain
Background/Purpose: In psoriatic arthritis (PsA) peripheral nociceptive pain is characteristic, and is trigger by the activation of the afferent sensory fibers in the inflamed synovial…
Abstract Number: 0365 • ACR Convergence 2020
Experience with Apremilast in Treatment of Psoriatic Arthritis in US Clinical Practice; Assessments from Trio Health and the American Rheumatology Network (ARN)
Colin Edgerton¹, Andrew Frick², Simon Helfgott³, Kent Kwas Huston⁴, Jasvinder Singh⁵ and Nehad Soloman⁶, ¹Articularis Healthcare, Summerville, SC, ²Trio Health, Louisville, CO, ³BWH- HMS, Boston, MA, ⁴Kansas City Physician Partners, Kansas City, MO, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ
Background/Purpose: Apremilast is the one targeted immune modulating (TIM) treatment for psoriatic arthritis (PsA) that may be combined with csDMARDs, biologic therapies, or used as…
Abstract Number: 0503 • ACR Convergence 2020
Targeted Metabolomic Profiling and Prediction of Cardiovascular Events: A Prospective Study of Patients with Psoriatic Arthritis and Psoriasis
Keith Colaco¹, Ker-Ai Lee², Shadi Akhtari³, Raz Winer⁴, Paul Welsh⁵, Naveed Sattar⁵, Iain McInnes⁶, Vinod Chandran⁷, Paula Harvey⁸, Richard Cook², Dafna Gladman⁷, Vincent Piguet⁸ and Lihi Eder⁹, ¹Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Women's College Hospital, University of Toronto, North York, ON, Canada, ⁴Rambam Health Care Campus, Haifa, Israel, ⁵University of Glasgow, Glasgow, Scotland, United Kingdom, ⁶Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁷Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁸Women's College Hospital, University of Toronto, Toronto, ON, Canada, ⁹Women’s College Research Institute, University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis and psoriasis, collectively termed psoriatic disease (PsD), are associated with increased cardiovascular (CV) risk. Metabolites comprise biomarkers that may add predictive value…
Abstract Number: 0889 • ACR Convergence 2020
Efficacy of Secukinumab Treatment in Patients with Early Psoriatic Arthritis: A Pooled Analysis of 4 Phase 3 Studies
Christopher Ritchlin¹, Alan Kivitz², Peter Nash³, Renato Calheiros⁴, Xiangyi Meng⁵, Corine Gaillez⁶, Bruce Kirkham⁷ and Iain McInnes⁸, ¹Department of Medicine, University of Rochester Medical Center, Rochester, NY, ²Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ³School of Medicine Griffith University, Brisbane, Queensland, Australia, ⁴Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) can progress quickly and lead to irreversible damage within 2 years of initial assessment if not treated.1 Secukinumab (SEC), a selective…
Abstract Number: 1027 • ACR Convergence 2020
The National Prevalence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2017
Sofia Exarchou¹, Johan K. Wallman², Daniela Di Giuseppe³, Gerd-Marie Alenius⁴, Eva Klingberg⁵, Valgerdur Sigurdardottir⁶, Sara Wedrén⁷, Ulf Lindström⁸, Carl Turesson⁹, Lennart T.H. Jacobsson¹⁰ and Johan Askling³, ¹Rheumatology, Department of Clinical Sciences Malmö, Lund University, Malmö, Sweden, Malmo, Sweden, ²Department of Clinical Sciences Lund, Rheumatology, Lund University, Sweden. Department of Rheumatology, Skåne University Hospital, Lund, Sweden., Lund, Sweden, ³Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, Stockholm, Sweden, ⁴Rheumatology, Norrland University Hospital, Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, Umeå, Sweden, ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Vastra Gotaland, Sweden, ⁶Rheumatology, Falun Hospital, Centre for Clinical Research Dalarna, Uppsala University, Falun, Sweden, Falun, Sweden, ⁷Rheumatology, Karolinska University Hospital, Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden., Stockholm, Sweden, ⁸Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden, ⁹Rheumatology, Department of Clinical Sciences Malmö, Lund University, Department of Rheumatology, Skåne University Hospital, Malmö, Sweden., Malmö, Sweden, ¹⁰Rheumatology, Department of Clinical Sciences, Malmö, Lund University. Department of Rheumatology and inflammation research, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden., Gothenburg, Sweden
Background/Purpose: Reported prevalence estimates of psoriatic arthritis (PsA) vary considerably, with few nationwide figures. This study aimed to estimate the prevalence of PsA among adults…
Abstract Number: 1343 • ACR Convergence 2020
Early Real-World Experience of Tofacitinib for Psoriatic Arthritis: Data from a United States Healthcare Claims Database
Philip Mease¹, Pamela Young², David Gruben³, Lara Fallon⁴, Rebecca Germino⁵ and Arthur Kavanaugh⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Pfizer Inc, Collegeville, PA, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Montreal, QC, Canada, ⁵Pfizer Inc, New York, NY, ⁶UC San Diego Health System, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). It was approved in the US in December 2017 for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].